Friday, 23 January 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 23 January 2026
News

Cancer vax combo keeps dazzling

Posted 22 January 2026 AM

Striking new data shows that Moderna's cancer vaccine in combination with MSD's Keytruda continued to halve the death rate for patients with resected high-risk melanoma, even after five years.

The companies announced "sustained improvement" in the primary endpoint of recurrence-free survival from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualised neoantigen therapy, in combination with Keytruda in patients with stage III/IV melanoma following resection.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (13)

Access & Reimbursement (1)

Clinical & Medical, R&D (4)

Regulatory, Pharmacovigilance & QA (5)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.